FindTrial
Sign In

Evinacumab

DRUG10 trials

Sponsors

Regeneron Pharmaceuticals, Daniel Gaudet

Conditions

Diabetic Kidney Disease (DKD)Dysbetalipoproteinemia (DBL)Healthy VolunteersHomozygous Familial HypercholesterolemiaHypercholesterolemiaHypertriglyceridemiaPediatric Homozygous Familial Hypercholesterolemia (HoFH)Severe Hypertriglyceridemia (HTG)

Phase 1

Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers
CompletedNCT03146416
Regeneron PharmaceuticalsHealthy Volunteers
Start: 2017-05-16End: 2018-06-14Updated: 2018-06-25

Phase 2

Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia
CompletedNCT03175367
Regeneron PharmaceuticalsHypercholesterolemia
Start: 2017-11-10End: 2020-12-14Updated: 2023-02-10
Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis
CompletedNCT03452228
Regeneron PharmaceuticalsSevere Hypertriglyceridemia (sHTG)
Start: 2018-06-07End: 2020-07-23Updated: 2023-02-16
Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis
TerminatedNCT04863014
Regeneron PharmaceuticalsHypertriglyceridemia
Start: 2021-07-12End: 2023-02-15Updated: 2024-05-22
Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease
RecruitingNCT07271186
Regeneron PharmaceuticalsDiabetic Kidney Disease (DKD)
Start: 2026-01-09End: 2028-04-07Target: 270Updated: 2026-03-17

Phase 3

Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
CompletedNCT03399786
Regeneron PharmaceuticalsHomozygous Familial Hypercholesterolemia
Start: 2018-01-18End: 2020-03-17Updated: 2021-05-18
Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
CompletedNCT03409744
Regeneron PharmaceuticalsHomozygous Familial Hypercholesterolemia
Start: 2018-03-13End: 2023-04-13Updated: 2025-04-08
Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia
CompletedNCT04233918
Regeneron PharmaceuticalsHomozygous Familial Hypercholesterolemia
Start: 2020-06-29End: 2023-05-30Updated: 2024-07-16
Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia
CompletedNCT05611528
Daniel GaudetHomozygous Familial Hypercholesterolemia
Start: 2023-02-21End: 2025-03-18Updated: 2025-03-25

Unknown Phase

Compassionate Use of Evinacumab
NCT06500598
Regeneron PharmaceuticalsDysbetalipoproteinemia (DBL), Pediatric Homozygous Familial Hypercholesterolemia (HoFH), Severe Hypertriglyceridemia (HTG)
Updated: 2025-10-28

Related Papers

Evinacumab in patients aged 5-17 years with homozygous familial hypercholesterolemia.
2025-12-22
Efficacy of evinacumab in patients with severe hypertriglyceridemia and a history of severe hypertriglyceridemia-related acute pancreatitis: A phase 2b trial.
2025-07-181 citations
Evinacumab for Homozygous Familial Hypercholesterolemia: The Italian Cohort of the ELIPSE HoFH Study.
2025-04-021 citations
Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy
European Heart Journal2024-06-1049 citations
Evinacumab Reduces Triglyceride-Rich Lipoproteins in Patients with Hyperlipidemia: A Post-Hoc Analysis of Three Randomized Clinical Trials.
2024-03-067 citations
Abstract 16672: Effects of Evinacumab on Atherogenic Lipoproteins in Children and Adolescents From Ages 5 to 17 Years With Homozygous Familial Hypercholesterolemia
Circulation2023-11-07
Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia
Circulation2023-10-2071 citations
The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia.
2023-10-1115 citations
Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia
JAMA Cardiology2023-09-1325 citations
Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial
Nature Medicine2023-03-01107 citations
Abstract 12756: Long-Term Efficacy and Safety of Evinacumab in Adult and Adolescent Patients With Homozygous Familial Hypercholesterolemia
Circulation2021-11-164 citations
Abstract 12066: The Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
Circulation2021-11-163 citations
Abstract 12054: Evinacumab Reduces Atherogenic Lipids and Apolipoprotein B in Patients With Severe Hypertriglyceridemia
Circulation2021-11-162 citations
Abstract 12027: Low-Density Lipoprotein Cholesterol in Patients With Homozygous Familial Hypercholesterolemia Who Participated in Sequential Studies of Alirocumab and Evinacumab
Circulation2021-11-161 citations
Marked plaque regression in homozygous familial hypercholesterolemia.
2021-05-0346 citations
Abstract 14267: Evinacumab Lowers LDL-C in Patients With Homozygous Familial Hypercholesterolemia Irrespective of Background Lipid-lowering Medication
Circulation2020-11-172 citations
Abstract 14407: The Longer-term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
Circulation2020-11-172 citations
Abstract 14270: The Effect of Evinacumab on Apheresis Eligibility in Patients With Homozygous Familial Hypercholesterolemia
Circulation2020-11-17
Evinacumab in Patients with Refractory Hypercholesterolemia
New England Journal of Medicine2020-11-15283 citations
Evinacumab for Homozygous Familial Hypercholesterolemia
New England Journal of Medicine2020-08-20701 citations

1 more papers not shown